Aurora Cannabis Q1 Earnings Call Highlights
Aurora Cannabis (ACB) reported Q1 adjusted SG&A of C$35.1M, down from C$36.1M a year earlier. Free cash flow was a C$5.8M outflow versus a C$6.8M inflow prior year, tied to lower gross profit before fair-value adjustments. Aurora ended with nearly C$150M cash and no debt, acquired Safari Flower, and reaffirmed its fiscal 2027 outlook.
How this was made
The 30-second read
Why it matters
Management portrays fiscal 2027 as transitional, with Canada reimbursement cuts weighing results while Germany-led international growth and EU GMP expansion partially offset. Q2 is guided to be sequentially higher in revenue and adjusted EBITDA.
Market read
Traders can reassess near-term earnings trajectory (Canada reimbursement drag) versus the credibility/timing of Germany and EU GMP capacity growth, using the reiterated Q2 sequential guidance and fiscal 2027 outlook.
What to watch
The article notes a C$9.7m reduction in gross profit before fair-value adjustments driving free cash flow outflow, but does not quantify how much of Safari’s contribution is sustainable versus one-time effects.
Background
Aurora Cannabis’ Q1 call discusses cost trends, liquidity, international medical expansion (including Safari Flower and EU GMP capacity), and the impact of Canada’s April 1 reimbursement revisions.
Ticker impact
Aurora Cannabis reaffirmed its fiscal 2027 outlook and guided Q2 revenue and adjusted EBITDA sequentially higher, citing Germany-led growth and Canada reimbursement headwinds.
Likely modest, two-sided reaction: upside bias if investors trust the Germany/EU GMP ramp and Safari integration, offset by skepticism around free-cash-flow deterioration and Canada reimbursement pressure.
The article provides specific operational updates (Leuna expansion expected to double output, Safari EU GMP certification, genetics yield potential) plus explicit guidance direction (Q2 sequentially higher) and a liquidity snapshot (nearly C$150m cash equivalents, no debt). However, it does not include full financial tables or consensus comparisons, limiting conviction on magnitude.
Market effects
Reinforces the medical cannabis sector narrative that EU GMP capacity and genetics-driven yield improvements can partially offset reimbursement-driven volatility.
Highlights Germany as the key growth engine and Canada reimbursement as the main near-term drag for Canadian licensed producers.
Signals continued focus on EU-regulated medical markets (Germany, Poland, U.K.) and potential future U.S. rescheduling optionality.
Counterpoint
The liquidity and no-debt position may not be enough to offset margin and cash-flow pressure if Canada reimbursement impacts persist longer than management expects.
Key entities
- companyAurora Cannabis Inc
Canadian licensed producer of medical and consumer cannabis products, headquartered in Edmonton, Alberta.
- acquired_companySafari Flower Company
Ontario indoor cultivation and manufacturing facility acquired by Aurora, cited for EU GMP certification and capacity expansion.
- facilityLeuna facility (Germany)
Aurora facility nearing completion of an expansion expected to double annual flower output.
